Other Events ·
Ultragenyx Pharmaceutical Inc. and Baylor Research Institute entered into a settlement agreement with Esjay Pharma…
RAREUltragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. and Baylor Research Institute entered into a settlement agreement with Esjay Pharma resolving patent litigation regarding the generic version of DOJOLVI (triheptanoin). The Company granted Esjay a non-exclusive, royalty-free license to market its generic version beginning January 1, 2033, potentially extending to July 1, 2033 if pediatric exclusivity is granted. Similar patent litigation against other ANDA filers remains pending in the U.S. District Court for the District of New Jersey. The settlement will be submitted to the Federal Trade Commission and Department of Justice as required by law. Ultragenyx Pharmaceutical Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for rare genetic diseases.